徳島大学 教育・研究者情報データベース(EDB)

Education and Research Database (EDB), Tokushima University

徳島大学ウェブサイトへのリンク

著作: Yoh Kousei/[髙田 信二郎]/Yoshimura Noriko/Hashimoto Jun/Efficacy, tolerability, and safety of risedronate in Japanese patients with Paget's disease of bone./[Journal of Bone and Mineral Metabolism]

ヘルプを読む

「著作」(著作(著書,論文,レター,国際会議など))は,研究業績にかかる著作(著書,論文,レター,国際会議など)を登録するテーブルです. (この情報が属するテーブルの詳細な定義を見る)

  • 項目名の部分にマウスカーソルを置いて少し待つと,項目の簡単な説明がツールチップ表示されます.

この情報をEDB閲覧画面で開く

EID
236512
EOID
655134
Map
0
LastModified
2012年8月29日(水) 15:15:07
Operator
大家 隆弘
Avail
TRUE
Censor
0
Owner
[部長]/[徳島大学.病院.中央診療施設等.リハビリテーション部]
Read
継承
Write
継承
Delete
継承
種別 必須
言語 必須 英語
招待 推奨
審査 推奨
カテゴリ 推奨
共著種別 推奨
学究種別 推奨
組織 推奨
著者 必須
  1. (英) Yoh Kousei
    役割 任意
    貢献度 任意
    学籍番号 推奨
  2. 髙田 信二郎
    役割 任意
    貢献度 任意
    学籍番号 推奨
  3. (英) Yoshimura Noriko
    役割 任意
    貢献度 任意
    学籍番号 推奨
  4. (英) Hashimoto Jun
    役割 任意
    貢献度 任意
    学籍番号 推奨
題名 必須

(英) Efficacy, tolerability, and safety of risedronate in Japanese patients with Paget's disease of bone.

副題 任意
要約 任意

(英) This study evaluated the clinical efficacy of treatment with oral risedronate (17.5 mg once daily) for 8 weeks in 11 Japanese patients with Paget's disease of bone (PDB). Risedronate suppressed the excessive bone turnover associated with PDB and improved several biochemical markers, including serum alkaline phosphatase (ALP), serum bone-specific ALP (BALP), urinary deoxypyridinoline (DPD), and urinary cross-linked N-telopeptide of type 1 collagen (NTX). These markers began to decrease within about 2 weeks after the initiation of treatment in most patients, and the response persisted for up to 40 weeks after the cessation of treatment. Risedronate reduced pain by week 24 in most patients. According to quantitative bone scintigraphy, the lesion with the highest radioisotope (RI) uptake showed a decrease of uptake from 12.7 +/- 6.8 to 6.0 +/- 2.3 (mean +/- SD) in week 24, although each lesion of patients with polyostotic disease had a different scintigraphic response. Overall, risedronate at a dose of 17.5 mg once daily was well tolerated by patients with PDB, even though the dosage was seven times higher than that approved for the treatment of osteoporosis in Japan (2.5 mg once daily). In conclusion, treatment with high-dose risedronate for 8 weeks resulted in clinically significant and sustained improvement of biochemical markers of bone turnover for 48 weeks in patients with PDB, and this improvement was associated with a decrease of RI uptake by Paget's bone lesions and with reduced pain.

キーワード 推奨
  1. (英) Adult
  2. (英) Aged
  3. (英) Aged, 80 and over
  4. (英) Bone Density Conservation Agents
  5. (英) Etidronic Acid
  6. (英) Female
  7. (英) Humans
  8. (英) Male
  9. (英) Middle Aged
  10. (英) Osteitis Deformans
  11. (英) Treatment Outcome
発行所 推奨
誌名 必須 Journal of Bone and Mineral Metabolism([Springer-Verlag])
(pISSN: 0914-8779, eISSN: 1435-5604)
ISSN 任意 1435-5604
ISSN: 0914-8779 (pISSN: 0914-8779, eISSN: 1435-5604)
Title: Journal of bone and mineral metabolism
Title(ISO): J Bone Miner Metab
Supplier: Springer Online Journal Archive
Publisher: Springer
 (NLM Catalog  (医中誌Web  (Scopus  (CrossRef (Scopus information is found. [need login])
必須 28
必須 4
必須 468 476
都市 任意
年月日 必須 2010年 2月 24日
URL 任意
DOI 任意 10.1007/s00774-009-0152-9    (→Scopusで検索)
PMID 任意 20179977    (→Scopusで検索)
NAID 任意
WOS 任意
Scopus 任意
評価値 任意
被引用数 任意
指導教員 推奨
備考 任意
  1. (英) Article.Affiliation: Department of Orthopedic Surgery, Sasayama Hospital, Hyogo Medical College, 75 Yamauchi-cho, Sasayama 669-2337, Japan. k-yoh@hyo-med.ac.jp

  2. (英) Article.PublicationTypeList.PublicationType: Clinical Trial, Phase III

  3. (英) Article.PublicationTypeList.PublicationType: Journal Article

  4. (英) Article.PublicationTypeList.PublicationType: Multicenter Study

  5. (英) Article.PublicationTypeList.PublicationType: Research Support, Non-U.S. Gov't